Inclusion Criteria:

- Patients must have pathologically confirmed, previously untreated, resectable,
squamous cell carcinoma of the larynx.

- Disease must be Stage III or IV.

- Tumor must be potentially surgically resectable and curable with conventional surgery
and radiation therapy.

- Patients must undergo pre-treatment endoscopic tumor staging and CT scanning.

- ECOG Performance status 0-2

- Pre-treatment laboratory criteria:

- WBC > or = to 3500/ul, granulocyte > or = to 1500/ul.

- Platelet count > or equal to 100,000/ul.

- Calculated or measured creatinine clearance > or = to 60 cc/min.

- Total Bilirubin < or = to 1.5 X ULN.

- AST and ALT < or = to 2.5 X ULN.

- Patients must give documented informed consent to participate in this study.

Exclusion Criteria:

- Prior head and neck malignancy or history of other prior non-head and neck malignancy
within the past 3 years.

- Prior head and neck radiation or prior chemotherapy.

- Documented evidence of distant metastases.

- Active infection.

- Pregnancy or lactation. Patients must agree to use adequate contraception (hormonal
or barrier method of birth control) prior to study entry, for the duration of study
participation and for 3 months after discontinuing therapy.

- Any medical or psychiatric illness which in the opinion of the principal investigator
would compromise the patients ability to tolerate this treatment.

- Patients residing in prison.

- Age < 18 years.

- Patients with psychiatric/social situations that would limit compliance with study
requirements are not eligible.

- Patients with prior radiation to the head and neck.

- Patients with prior anti-epidermal growth-factor receptor antibody therapy or therapy
with a tyrosine-kinase inhibitor.

- Patients with Grade > 2 peripheral neuropathy.

- Any history of severe hypersensitivity reaction to docetaxel or other drugs
formulated with polysorbate 80.